Following this discovery, a potent PARP10 inhibitor, A82-(CONHMe)-B354, has also been developed, although further research is needed to determine its efficacy against tumor cells and its role as a future therapeutic agent [118]. This evidence concerns the gene PARP10 and neoplasm.